Search results for "Bladder carcinoma"

showing 8 items of 8 documents

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-i…

2010

Abstract OBJECTIVE: To evaluate the efficacy of 1-year maintenance after a 6-week cycle of early intravesical chemotherapy, as the role of maintenance in intravesical chemotherapy is debated. PATIENTS AND METHODS: Between May 2002 and August 2003, 577 patients with non-muscle-invasive bladder cancer (NMI-BC) underwent transurethral resection (TUR) and early intravesical chemotherapy (epirubicin, 80 mg/50 mL). They were randomized between a 6-week induction cycle and the induction cycle plus maintenance with 10 monthly instillations. In all, 95 patients with T1G3, Tis or single and primary Ta-T1 G1-G2 tumours were excluded; 482 patients at intermediate risk of recurrence continued the study.…

AdultAged 80 and overMaleAntibiotics AntineoplasticRemission InductionCystoscopyintravesical chemotherapy bladder carcinomaMiddle AgedCombined Modality TherapySettore MED/24 - UrologiaAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsHumansFemaleNeoplasm Recurrence LocalEpidemiologic MethodsAgedEpirubicin
researchProduct

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentUrologySettore MED/24 - UrologiaSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 1Stage (cooking)AgedRetrospective StudiesChemotherapyHematologyUrinary bladderbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisDrug Resistance MultipleGene Expression Regulation NeoplasticTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsChemotherapy AdjuvantDrug Resistance NeoplasmChemoprophylaxisFemaleSuperficial Bladder CarcinomaGenes MDRNeoplasm Recurrence LocalbusinessFollow-Up StudiesJournal of cancer research and clinical oncology
researchProduct

Cigarette Smoking and Drinking Water Source: Correlation with Clinical Features and Pathology of Superficial Bladder Carcinoma

2007

<i>Objective:</i> Water source and cigarette smoking are related to clinical characteristics and pathology of superficial transitional cell carcinoma of the bladder. <i>Methods:</i> Tumor number, dimension, G-grade, T-stage, recurrences, cigarette smoking and water supply were recorded in patients harboring Ta–T1 G1–3 transitional cell carcinoma of the bladder. <i>Results:</i> Of 577 patients, 61% had multiple and 36% recurrent tumors. Two hundred and forty-one patients (42%) were current smokers and 188 (33%) were former smokers. Bottled water was the only drinkable source for 249 (45%) patients, municipal water supply for 177 (32%), artesian wells for 3…

AdultMalePathologymedicine.medical_specialtyUrologyWater sourceRisk AssessmentCigarette smokingRecurrenceRisk FactorsWater SupplyOdds RatioCarcinomaHumansMedicineWater PollutantsAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industrySmokingdigestive oral and skin physiologyOdds ratioMiddle Agedmedicine.diseaseTransitional cell carcinomaItalyUrinary Bladder NeoplasmsMultivariate AnalysisFemaleNeoplasm stagingSuperficial Bladder CarcinomabusinessUrologia Internationalis
researchProduct

Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?

2003

Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. T…

MaleCarcinoma Transitional CellCancer ResearchATP Binding Cassette Transporter Subfamily BBladder carcinomaImmunohistochemistryIntravesical chemotherapySettore MED/24 - UrologiaAdministration IntravesicalUrinary Bladder NeoplasmsOncologyDrug Resistance NeoplasmPredictive Value of TestsGP-170HumansFemaleMDR-1ChemoresistanceGlycoproteinsNeoplasm StagingRetrospective Studies
researchProduct

Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control stud…

2007

OBJECTIVES: To identify risk factors of carcinoma of the extrahepatic biliary tract in men. METHODS: Newly diagnosed and histologically confirmed patients, 35-70 years old, were interviewed between 1995 and 1997 in Denmark, Sweden, France, Germany and Italy. Population controls were frequency-matched by age and region. Adjusted odds ratios and 95%-confidence intervals were estimated by logistic regression. RESULTS: The analysis included 153 patients and 1421 controls. The participation proportion was 71% for patients and 61% for controls. Gallstone disease was corroborated as a risk factor for extrahepatic biliary tract carcinoma in men (odds ratio 2.49; 95% confidence interval 1.32-4.70), …

MaleobesityEtiologyEpidemiologyMedizinGastroenterologyBody Mass Index0302 clinical medicineBile Ducts ExtrahepaticCholelithiasisRisk FactorsMedicineAlcohol consumption2. Zero hungerBiliary tract neoplasmeducation.field_of_studySmokingGastroenterologyCase-control studyMenGallstonesMiddle Agedmedical history3. Good healthBiliary tract carcinomaBiliary Tract Neoplasms030220 oncology & carcinogenesisMedical history030211 gastroenterology & hepatologyGallbladder NeoplasmsepidemiologyGallbladder carcinomaAdultmedicine.medical_specialtyAmpulla of Vateralcohol consumptioncase-control studyetiologyPopulationCommon Bile Duct Neoplasmsmensmoking03 medical and health sciencesInternal medicinesmoking.HumansObesityRisk factoreducationLife StyleAgedbiliary tract carcinomaHepatologybusiness.industryCase-control studyOdds ratiomedicine.diseaseConfidence interval[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control Studies[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiegallbladder carcinomabusinessBody mass index
researchProduct

A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder canc…

2021

Introduction: BCG and MMC shortage and Covid-19 pandemic, more recently, limit accessibility to maintenance regimen in intravesical prophylaxis against recurrence of non-muscle invasive bladder cancer (NMIBC). Ellagic acid (EA) and Annona muricata (AM) exert antitumor activity against different human tumours. An observational prospective study on the prophylactic effect of oral administration of EA+AM in patients avoiding maintenance regimen is presented. Materials and methods: Patients affected by NMIBC and not undergoing maintenance after a 6-week course of intravesical prophylaxis with MMC or BCG were entered. Tis and very high-risk tumours were excluded. After informed consent, the pati…

bladder carcinomamedicine.medical_specialtybacillus calmette-guerinmedicine.medical_treatment030232 urology & nephrologyAdministration Oralnutraceuticsintravesical instillationGastroenterologyAnnonalaw.inventionannona muricata03 medical and health sciences0302 clinical medicineAdjuvants ImmunologicRandomized controlled trialellagic acidOral administrationlawInternal medicineCytologymedicineHumansNeoplasm InvasivenessProspective StudiesProspective cohort studyPandemicsChemotherapyBladder cancermedicine.diagnostic_testSARS-CoV-2business.industryCOVID-19General MedicineCystoscopymedicine.diseaseRegimenAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccineNeoplasm Recurrence Localbusinessannona muricata; bacillus calmette-guerin; bladder carcinoma; ellagic acid; intravesical instillation; nutraceuticsUrologia Journal
researchProduct

Optimizing intravesical chemotherapy in patients with non muscle invasive bladder carcinoma.

2008

intravesical chemotherapy bladder cancer non muscle invasive bladder carcinoma
researchProduct

A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculos…

2016

Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis…

medicine.medical_specialtyCancer ResearchComplicationsSettore MED/17 - Malattie InfettiveEpidemiologyBladder030232 urology & nephrologyUrologyShort ReportInfectious DiseaseGastroenterologySepsis03 medical and health sciences0302 clinical medicineInternal medicinemedicineGranulomatous prostatitisBladder; Calmette; Complications; Guérin; Intravesical; Infectious Diseases; Oncology; Epidemiology; Cancer ResearchPneumonitisHepatitisLatent tuberculosisbusiness.industryIntravesicalIsoniazidmedicine.diseaseInfectious DiseasesOncology030220 oncology & carcinogenesisOrchitisSuperficial Bladder CarcinomabusinessComplicationGuérinmedicine.drugCalmetteInfectious Agents and Cancer
researchProduct